Superworth

Biocryst Pharmaceuticals price to free cash flow BCRX

Market value divided by free cash flow over the last twelve months, since 2025.

Today, Nov 2, 2026
5.6×
Peer median
33.6×

Biocryst Pharmaceuticals' price to free cash flow is 5.6× as of Nov 2, 2026.

The median for 9 biotech stocks of a similar size is 33.6×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.6×5.2×33.0×
202533.6×30.7×114×

Against its peers

Companies in Biotechnology nearest Biocryst Pharmaceuticals' size, closest first, today.

CompanyPrice to free cash flow
BCRXBiocryst Pharmaceuticals5.6×
VCELVericel33.6×
ADMAAdma Biologics21.3×
MGTXMeiraGTx85.5×
KRYSKrystal Biotech34.0×
RGENRepligen87.2×
TECHBIO-TECHNE43.3×
HALOHalozyme Therapeutics18.2×
NBIXNeurocrine Biosciences17.0×
EXELExelixis14.8×
Peer median33.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Biocryst Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.